Navigation Links
MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug
Date:5/26/2011

MOUNTAIN VIEW, Calif., May 26, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults. According to the National Headache Foundation, approximately 30 million people in the United States suffer from migraine, a debilitating neurological disorder. Common symptoms of migraine include recurrent headaches, nausea, phonophobia (sensitivity to sound) and photophobia (sensitivity to light).

"This NDA submission marks a major corporate milestone for MAP Pharmaceuticals and brings us one step closer to our goal of providing the underserved migraine patient population with a potential new treatment option," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "Our comprehensive development program evaluated LEVADEX in approximately 1,000 patients for up to one year, treating nearly 10,000 migraines. If approved by the FDA, LEVADEX could potentially provide a new treatment option for migraine sufferers, including the millions of patients whose migraines are not well treated today."

The 505(b)(2) NDA submission is based on a comprehensive development program for LEVADEX, and includes efficacy and safety data from the Phase 3 FREEDOM-301 clinical trial that has been presented at scientific conferences and was recently published in Headache: The Journal of Head and Face Pain. In the FREEDOM-301 trial, patients self-administered LEVADEX at home using the Company's proprietary TEMPO® inhaler. LEVADEX contains a novel formulation of dihydroergotamine (DHE).  Patients taking LEVADEX in this pivotal trial had statistically significant improvement at two hours compared to patients on placebo for all four c
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Watson Acquires Specifar Pharmaceuticals
2. Auxilium Pharmaceuticals, Inc. Updates Launch Progress of XIAPEX® in EU
3. BioMarin to Present at the UBS Global Specialty Pharmaceuticals Conference
4. Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
5. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
6. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
7. Vanda Pharmaceuticals Reports First Quarter 2011 Results
8. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
9. Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
10. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
11. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... (PRWEB) October 19, 2014 The ... (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin ... Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast ... major drivers, restraints, challenges, opportunities, current market trends, ... along with the estimates and forecasts of the ...
(Date:10/18/2014)... October 18, 2014 The Asia-Pacific hardware ... market in Asia-Pacific with analysis and forecast of revenue. ... is expected to reach $51,362.6 million by 2018, at ... Browse through the TOC of the Asia-Pacific hardware encryption ... analysis provided. This also provides a glimpse of the ...
(Date:10/18/2014)... According to a new market research ... - Global Trends & Forecasts up till 2017”, hydraulic ... 2011. This value is expected to increase from $40 ... 10% CAGR during the same period. North America is ... in terms of hydraulic horse power supplied by the ...
(Date:10/17/2014)... looking-glass to Wonderland, mirrors in the real world can ... new class of mirror that works like no other. ... (OSA) new high-impact journal Optica , ... type of mirror that forgoes a familiar shiny metallic ... unusual magnetic property of a non-metallic metamaterial. , ...
Breaking Biology Technology:Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 2Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 4Magnetic mirrors enable new technologies by reflecting light in uncanny ways 2Magnetic mirrors enable new technologies by reflecting light in uncanny ways 3Magnetic mirrors enable new technologies by reflecting light in uncanny ways 4
... of Approximately DKK 232.7, Million From GSK for Achievement of Positive Results ... ... Study, COPENHAGEN, August 21 Genmab A/S (OMX: GEN),announced today ... its collaboration with GlaxoSmithKline,(GSK). A milestone payment of approximately DKK 232.7 million,(approximately ...
... ... - Total Fiscal Year Revenues of $79.8M increased 15% and adjusted EPS* of ... $0.99 increased 87% -, EXTON, Pa., Aug. ... quarter and fiscal,year ended June 30, 2008., Fourth Quarter Results, Revenues: Sales and ...
... and the ferromagnet iron are the basis for much ... electric motors. In this week,s issue of the journal ... scientists, including academic and industrial researchers from the UK, ... elements with a small amount of another common metal, ...
Cached Biology Technology:Genmab Reaches Fifth Milestone in Ofatumumab Collaboration 2Genmab Reaches Fifth Milestone in Ofatumumab Collaboration 3Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 2Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 3Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 4Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 5Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 6Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 8Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 9Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 10Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 11Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 12Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 13Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 14Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 15Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 16Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 17Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 18Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 19Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 20Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 21Creating unconventional metals 2
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to ... the development of skin cancers by turning on an ... skin cells. , Previously considered protective, SIRT6 is part ... help regulate genomic stability and prevent some of the ... damage, which can lead to cancer. This study, in ...
(Date:10/14/2014)... Mount Sinai-led research team has discovered a new kind of ... a cell that lines liver blood vessels, according to a ... . The existence of such a cell type contradicts current ... embryo, and may hold clues to origins of, and future ... from a single cell into a complex being made up ...
(Date:10/14/2014)... This week, an international team of researchers, led by ... in the journal Nature Genetics a brief ... 360 varieties of the tomato plant. , The C.M. ... an important role in this study by providing seed ... , This study, which builds on the first tomato ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3
... gene-related peptide are the main neuropeptides in peripheral nerve ganglia, ... system. In a study by Dr. Changma Fu and co-workers ... model of sciatic nerve defect was prepared by dissecting the ... Dawley rats. The two ends of the nerve were encased ...
... and Norway have completed a comprehensive genomic analysis of ... recurrent genetic mutations not previously found in cervical cancer, ... been approved for other forms of cancer. The findings ... plays in the development of cervical cancer. ...
... Studies has been awarded $A28m by the Australian Research Council ... three new research programs - People and Ecosystems, Ecosystem Dynamics: ... , Centre Director, Professor Terry Hughes said that "the vision ... reefs and their interaction with people, in order to foster ...
Cached Biology News:International team completes systematic, genomic study of cervical cancer 2International team completes systematic, genomic study of cervical cancer 3International team completes systematic, genomic study of cervical cancer 4International team completes systematic, genomic study of cervical cancer 5
... The new Thermo Electron RapidStak provides valuable ... Utilizing a unique buffer nest technology for ... the RapidStak provides fast, reliable automation for ... and walk-away confidence. The RapidStak can be ...
Recombinant Rhesus Monkey IFN Alpha Activity: 2.9 x 10 8 u/mg...
... N 2 NaO 7 S 2 Formula ... powder Identity: By IR epsilon max (615 ... or equal to 60 x 10 3 ... 10.0% lambda max (H 2 O ...
... spectrofluorometer with a minimum 1 nm resolution ... or greater for the Raman band of ... keep in mind in order to meet ... or anisotropic measurements. ,The FP-6500 is designed ...
Biology Products: